ALKS 2680 for Narcolepsy

This trial tests a new treatment called ALKS 2680 for individuals with sleep disorders such as Narcolepsy Type 1, Narcolepsy Type 2, and Idiopathic Hypersomnia (characterized by excessive daytime sleepiness without a known cause). The trial aims to assess the safety and effectiveness of this treatment over time. It is designed for those who have already participated in a related study and can safely discontinue other narcolepsy medications. Participants should have experience with frequent sleep attacks or excessive daytime sleepiness. As a Phase 3 trial, this treatment represents the final step before FDA approval, offering participants a chance to contribute to its potential availability for wider use.

Yes, you will need to stop taking any medications prescribed for managing narcolepsy symptoms for a certain period before starting the trial and for the entire duration of the study.

Research has shown that ALKS 2680 is likely safe. In earlier studies, most participants tolerated ALKS 2680 well. They felt more awake compared to those who took a placebo, experiencing increased alertness without serious side effects. Another study found the treatment safe for both healthy adults and those with conditions like narcolepsy or idiopathic hypersomnia, which cause excessive daytime sleepiness. So far, evidence suggests ALKS 2680 could be a safe option for treating sleep disorders.¹²³⁴⁵

Unlike the standard treatments for narcolepsy, which typically include medications like modafinil or sodium oxybate, ALKS 2680 offers a novel approach. This treatment works through a unique mechanism of action, targeting specific receptors in the brain to improve wakefulness. Researchers are excited about ALKS 2680 because it could potentially offer faster results and fewer side effects compared to existing options. Additionally, its potential effectiveness in treating both types of narcolepsy and idiopathic hypersomnia makes it a versatile option for patients with different sleep disorders.

Research has shown that ALKS 2680, also known as alixorexton, may help treat sleep disorders such as narcolepsy. In this trial, participants with Narcolepsy Type 1, Narcolepsy Type 2, or Idiopathic Hypersomnia will receive ALKS 2680. Studies have found that it significantly improves wakefulness and reduces daytime sleepiness in people with Narcolepsy Type 1. The treatment activates certain receptors in the brain that promote wakefulness. Early results suggest that ALKS 2680 is safe and more effective than a placebo at improving alertness. This makes it a potential option for those experiencing excessive sleepiness due to narcolepsy or idiopathic hypersomnia.¹²⁶⁷⁸